GlaxoSmithKline (GSK) Price & Analysis

Compare

4,984 Followers

GSK Stock Chart & Stats

Day’s Range― - ―

52-Week Range$31.72 - $45.01

Previous CloseN/A

Volume981.79K

Average Volume (3M)5.11M

Market Cap

$78.10B

Enterprise Value$51.48B

Total Cash (Recent Filing)$4.49B

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)19.8

Beta0.26

Next Earnings

Jul 30, 2025

EPS Estimate

1.15

Last Dividend Ex-Date

May 16, 2025

Dividend Yield3.96%

Share Statistics

EPS (TTM)1.20

Shares Outstanding2,050,381,600

10 Day Avg. Volume5,206,153

30 Day Avg. Volume5,105,490

Financial Highlights & Ratios

PEG Ratio0.81

Price to Book (P/B)3.97

Price to Sales (P/S)0.00

P/FCF Ratio15.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$40.13

Price Target Upside3.80% Upside

Rating ConsensusHold

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

AcquisitionThe acquisition of efimosfermin is sound given that it expands GSK's hepatology portfolio, provides optionality to related diseases, and fits within GSK's BD strategy.

Competitive AdvantageGSK noted the manufacturing for Trelegy is even more complicated than those devices, which suggests a competitive advantage.

Bears Say

Manufacturing ComplexityThe complexity of manufacturing for Trelegy suggests potential challenges in production.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

―

Insiders

5.81% Mutual Funds

10.36% Other Institutional Investors

83.56% Public Companies and Individual Investors

Detailed Ownership Overview >

GSK FAQ

What was GlaxoSmithKline’s price range in the past 12 months?

GlaxoSmithKline lowest stock price was $31.71 and its highest was $45.01 in the past 12 months.

What is GlaxoSmithKline’s market cap?

GlaxoSmithKline’s market cap is $78.10B.

When is GlaxoSmithKline’s upcoming earnings report date?

GlaxoSmithKline’s upcoming earnings report date is Jul 30, 2025 which is in 63 days.

How were GlaxoSmithKline’s earnings last quarter?

GlaxoSmithKline released its earnings results on Apr 30, 2025. The company reported $1.199 earnings per share for the quarter, beating the consensus estimate of $1.045 by $0.154.

Is GlaxoSmithKline overvalued?

According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does GlaxoSmithKline pay dividends?

GlaxoSmithKline pays a Quarterly dividend of $0.421 which represents an annual dividend yield of 3.96%. See more information on GlaxoSmithKline dividends here

What is GlaxoSmithKline’s EPS estimate?

GlaxoSmithKline’s EPS estimate is 1.15.

How many shares outstanding does GlaxoSmithKline have?

GlaxoSmithKline has 2,050,381,600 shares outstanding.

What happened to GlaxoSmithKline’s price movement after its last earnings report?

GlaxoSmithKline reported an EPS of $1.199 in its last earnings report, beating expectations of $1.045. Following the earnings report the stock price went up 2.258%.

Which hedge fund is a major shareholder of GlaxoSmithKline?

Currently, no hedge funds are holding shares in GSK

GlaxoSmithKline Stock Smart Score

Outperform

Fundamentals

Return on Equity

22.26%

Trailing 12-Months

Asset Growth

6.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

GlaxoSmithKline

GlaxoSmithKline (GSK) is a leading global healthcare company that researches, develops, and manufactures innovative pharmaceutical medicines, vaccines, and consumer healthcare products. The company operates in three main segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. GSK's core products include treatments for respiratory diseases, HIV, immuno-inflammation, and oncology, as well as a broad range of vaccines and over-the-counter consumer health products.

GSK Company Deck

GSK Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong growth in specialty medicines and promising R&D advancements, positioning GSK for continued success. However, challenges such as declining vaccine sales, macroeconomic uncertainties, and impacts from Medicare Part D redesign were notable concerns. Despite these issues, the overall sentiment remains positive due to strategic growth areas and confident long-term outlooks.Read More>

GSK Stock 12 Month Forecast

Average Price Target

$40.13

▲( 3.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","39":"$39","46":"$46","35.5":"$35.5","42.5":"$42.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,35.5,39,42.5,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Dec<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.32,38.83384615384615,39.347692307692306,39.86153846153846,40.37538461538462,40.88923076923077,41.403076923076924,41.91692307692308,42.43076923076923,42.94461538461538,43.458461538461535,43.972307692307695,44.48615384615385,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.32,38.45923076923077,38.59846153846154,38.737692307692306,38.87692307692308,39.01615384615385,39.15538461538462,39.29461538461538,39.433846153846154,39.573076923076925,39.7123076923077,39.85153846153846,39.99076923076923,{"y":40.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.32,38.08384615384615,37.847692307692306,37.61153846153846,37.37538461538462,37.13923076923077,36.903076923076924,36.66692307692308,36.43076923076923,36.19461538461538,35.958461538461535,35.722307692307695,35.48615384615385,{"y":35.25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.97,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.34,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.48,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.56,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":34.5,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":37.44,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":38.32,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >